Amarin scored an FDA win with blockbuster potential last year when its fish oil-derivative Vascepa received a heart-helping nod on top of statins. Now, with Amarin's fleshed out sales force nearly in place and prescriptions soaring, the drugmaker is ready to take Vascepa to the next level.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,